INTRODUCTION
Chronic myeloid leukemia (CML) arises from a reciprocal chromosomal translocation (9;22) giving rise to the fusion gene bcr-abl. This oncogene encodes for the constitutively active tyrosine kinase BCR-ABL, which activates several downstream survival cascades resulting in enhanced proliferation, reduced apoptosis and aberrant adherence regulation. 1 The oncogenic action of BCR-ABL resembles deregulated cytokine signaling, which is reflected by induction of cytokine independent growth of hematopoietic cell lines transformed by BCR-ABL. 2 The tyrosine kinase inhibitor (TKI) imatinib mesylate (Glivec, Novartis, Basel, Switzerland) has revolutionized CML therapy. Patients treated with imatinib achieve excellent long-term responses with cumulative complete cytogenetic remission rates near to 90%. 3 However, persistent minimal residual disease despite continued treatment with imatinib implies the risk of late disease relapse. Additionally, a substantial proportion of patients progresses on imatinib therapy because of primary or secondary resistance mechanisms. 4 In 60 --90% secondary resistance to imatinib is governed by BCR-ABL-kinase point mutations, which led to the development of the second generation inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, Bristol-Myers-Squibb, Princeton, NJ, USA). 5 Nevertheless emergence of the so called 'gatekeeper' mutation T315I, which is resistant towards all currently available TKIs, predicts a poor prognosis with limited therapeutic options. 6 One persistent theme on potential CML-progenitor resistance mechanisms is activation of BCR-ABL bypass signaling proteins such as MAPKs or Jak2. 7, 8 Rescue of BCR-ABL-transformed murine Ba/F3 hematopoietic cells by interleukin 3 (IL3) has been demonstrated in the first in-vitro study demonstrating the selective antileukemic activity of imatinib. 9 We have shown that Ba/F3-BCR-ABL cell survival is associated with MAPK-activation in the presence of IL3. 10 Additionally, Ba/F3-BCR-ABL cells rapidly upregulate the common b-chain of the IL3-receptor (cCRbc) to compensate for loss of BCR-ABL activity during TKI-treatment. 11 Thus disruption of these signaling pathways could be an attractive target to combat resistance against TKI-treatment.
Recent reports showed favorable clinical response rates with omacetaxine mepesuccinate (OM, formerly homoharringtonine) in patients resistant towards two or more TKIs, especially in those harboring the T315I mutation. Even selective disappearance of the mutated T315I clone was observed. 12 This clinical observation is supported by preclinical data suggesting T315I-selective downregulation of BCR-ABL, and selective apoptogenic activity in progenitor cells. 13 Omacetaxine is a first in-class cetaxine, derived from the evergreen tree Cephalotaxus harringtonia native to the eastern part of Asia.
14 Together with TKIs (imatinib, nilotinib and dasatinib) and interferon-a, omacetaxine is one of the few drugs able to induce cytogenetic remissions with positive impact on the natural course of CML.
14 In order to characterize the molecular mechanisms of OM in CML, we explored its effects on various resistant cell lines and primary CML cells in vitro.
MATERIALS AND METHODS

Cell lines
Murine pre-B-cells Ba/F3 were grown in RPMI 1640 medium supplemented with 2% L-glutamine (Gibco BRL, Wiesbaden, Germany), 1% penicillin --streptomycin, 10% heat-inactivated fetal bovine serum (Gibco BRL) or 5% conditioned medium from WEHI-3 cells as a source of IL3. 15 BCR-ABLtransformed Ba/F3 (Ba/F3p210, Ba/F3p210-T315I) were derived as described previously by retroviral transfection using the mammalian expression vector pSRa. 16 The derivatives of the murine myeloid cell line 32D, 17 the BCR-ABL-transformed 32Dp210 and 32Dp210-T315I were grown under the same conditions. These cells were generated by Dr J Duyster (Munich, Germany), and provided by Dr H Kuip (Stuttgart, Germany). The human cell line KBM5s was derived from a patient with myeloid blast crisis CML, and was kindly provided by Drs M Beran and C Ricci (Houston, TX, USA). 18 The imatinib-resistant derivative KBM5r-T315I was generated by continuous culture in the presence of up to 1.0 mM of imatinib. It expresses the highly resistant BCR-ABL-mutant T315I, which cannot be detected in the maternal, imatinib-sensitive KBM5s line. 19 Parental cells were maintained without the drug, whereas KBM5r-T315I cells were continuously cultured in media supplemented with 1.0 mM imatinib. K562, a BCR-ABLpositive cell line also derived from a CML blast crisis patient was grown under the same media-conditions as described for the murine cell lines stated above. 20 All cell lines were grown in 5% CO 2 /95% O 2 atmosphere, in a 37 1C fully humidified incubator.
Drugs
OM was prepared as a 1.833 mM stock solution in 0.9% NaCl and was kindly provided by Dr A Craig (Chemgenex Pharmaceuticals, Menlo Park, CA, USA). Stock solution was stored at room temperature and freshly diluted (in cell line media) for each experiment to achieve the final concentration. Imatinib was prepared as a 10 mM stock in phosphate buffered saline. Nilotinib was kept in dimethyl sulfoxide dissolved drug stocks (10 mM). Both agents were kindly provided by Drs E Buchdunger and P Manley (Novartis). Stocks were kept at À20 1C and also freshly diluted (in cell line media) for each experiment. MG-132 (Sigma-Aldrich, Taufkirchen, Germany) was prepared as 10 mM stock solution in dimethyl sulfoxide, kept at À20 1C.
MTS-assay
Metabolic activity was evaluated using the MTS Cell Titer 96 Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. In brief, cells were plated in triplicate at 6 Â 10 3 cells per well and exposed to increasing concentrations of the respective drug dilutions. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxphenyl-2-(4-sulfophenyl)-2H-tetrazolium)) uptake was assayed daily (for 3 days) to ensure exponential growth of the untreated cells. Means and s.d. were generated from at least three independent experiments and reported as the percentage of growth versus control. Cell proliferation curves were derived from these data and IC 50 values were calculated.
Viability assay
Immortalized cell lines and primary CML cells were plated at 5 Â 10 5 --2 Â 10 6 cells/ml. After being incubated with defined drug concentrations for up to 48 h viable cells were counted by 0.4% trypan-blue exclusion. IC 50 values were analyzed by hand from the dose response plot.
Patient derived CD34 þ enriched CML-progenitor cells Primary cells were obtained from peripheral blood specimens of seven patients with newly diagnosed CML (chronic phase) treated within the German CML study group. Informed consent was obtained from all patients according to the declaration of Helsinki. Peripheral blood mononuclear cells were isolated by means of Ficoll-separation (FicollHypaque, Amersham Pharmacia, Uppsala, Sweden). CD34 þ progenitors cells were selected from peripheral blood mononuclear cells by using the CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. The selection procedure achieved a 95% purity when tested by flow cytometry. CD34 þ enriched cells were cultured in tissue-culture plates (Falcon; BD Biosciences, Franklin Lakes, NJ, USA) at 37 1C in a humidified atmosphere with 5% CO 2 in serum-free media (StemCell Technologies, Vancouver, BC, Canada). Serum-free-media was supplemented with cytokines (GF) at concentrations reported by Bhatia et al. 21 The cytokine mix contained 200 pg/ml granulocyte-macrophage colony-stimulating factor; 1 ng/ml granulocyte colony-stimulating factor; 200 pg/ml stem cell factor; 50 pg/ml leukemia inhibitory factor; 200 pg/ml macrophage-inflammatory protein-1a and 1 ng/ml interleukin 6 (all Cell Systems, St Katharinen, Germany). In experiments with high concentration GF mix, 25-fold higher concentrations of each cytokine were used.
Western blot analysis
Phosphate buffered saline-washed cells were lysed strictly on ice at 5 Â 10 7 cells per ml of Triton X-100-based lysis buffer containing 20 mM sodium fluoride, 1 mM sodium metavanadate, 1 mM phenylmethylsulfonylfluoride, 60 mg/ml bestatin, 60 mg/ml leupeptin and 60 mg/ml soybean trypsin inhibitor (all Sigma-Aldrich). Total protein was quantified using the Bradford assay (Bio-Rad, Munich, Germany). Equal amounts of protein were analyzed by immunoblotting with mouse monoclonal anti-abl (8E9, BD Pharmingen, Heidelberg, Germany), mouse monoclonal anti-pTyr (4G10, Upstate Biotechnology, Lake Placid, NY, USA), rabbit polyclonal anti-ERK1 (K-23, sc-94), monoclonal anti-pERK antibody (sc-7383, E-4 and Tyr204) and rabbit polyclonal IL-3/IL-5/GM-CSFRb antibody (K-17 and sc-678), all purchased from Santa Cruz (Heidelberg, Germany). Equal protein loading was ensured by blotting for actin with the mouse monoclonal anti-Actin (Ab-1) kit (Calbiochem, Darmstadt, Germany). Immunoblots were probed with a secondary horseradish peroxidase conjugated antibody either purchased from Promega or from Jackson ImmunoResearch (Suffolk, UK), and detected by using the enhanced chemiluminescence femto or pico kit (Pierce Biotechnology Inc., Rockford, IL, USA). Autoradiographs were scanned using the ChemiDoc XRS system (Bio-Rad) to quantify the signal intensity.
Apoptosis measurement
Staining for activated caspase-3 was performed using the (FITC)-conjugated polyclonal rabbit anti-active caspase-3 detection kit (BD Pharmingen) according to the manufacturer's instructions. Cells were analyzed within 1 h after staining. Acquisition and analysis were performed on a FACSCalibur flow cytometer (Becton Dickinson, Heidelberg, Germany) using Cell Quest software (Becton Dickinson). A minimum of 10 000 cells per sample were analyzed.
RNA extraction and cDNA synthesis
Total RNA was extracted from at least 5 Â 10 6 cells (primary CD34 þ enriched CML-progenitors) using the RNeasy Mini Kit (Qiagen, Hilden, Germany) or the Trizol reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. cDNA-synthesis was performed using random hexamer primers and MMLV reverse transcriptase (Invitrogen, Darmstadt, Germany).
Quantification of cCRbc-mRNA
Quantitative real-time reverse transcriptase polymerase chain reaction was performed to quantify cCRbc-mRNA expression relative to total b-glucoronidase (GUS) mRNA transcripts, using a modified LightCycler FastStart DNA Master plus SYBR Green I --kit and the LightCycler instrument 1.5. (Roche Diagnostics, Mannheim, Germany). Mastermix was prepared according to the kit protocol containing 2 ml cDNA template or plasmid dilution. Primer sequences were as follows: CSF2-10-F2 5 0 -GACA GCAAGACCGAGACCC-3 0 and CSF2-13-R1 5 0 -CTCCCGTTCTGGAACAGGTG-3 0 . Cycler conditions were the following: 10 min denaturation at 95 1C, 50 cycles of 10 s at 60 1C (annealing) and 26 s at 72 1C (elongation). A 5 log series of plasmid dilutions (see below) was amplified for quantification of cCRbc. Sample copy numbers were calculated by the LightCycler software (Roche Diagnostics).
For preparation of the plasmids, nested RT-PCR products were amplified from K562 cells using primers CSF2-10-F2, and CSF2-13-R1 by using the Expand high fidelity plus PCR system (Roche Diagnostics). PCR transcripts were cloned into the PCR2.1-TOPO vector and transduced into E. coli TOP10F' according to the manufacturers' instructions (Invitrogen). Plasmid DNA containing the cCRbc construct was isolated using the Plasmid Midi and Maxi Kit (Qiagen). Bidirectional direct sequencing confirmed inserts. The cloned plasmid was linearized by XbaI digestion at 37 1C for 2h followed by heat inactivation at 65 1C for 20 min. As internal control GUS mRNA transcripts were measured using standard plasmid (pME-2) containing GUS sequences. Linearized plasmid dilutions were prepared in 10 mM Tris-HCl pH 8.0, 1 mM EDTA containing 20 mg/ml tRNA (Roche Diagnostics).
Data analysis
Statistical analysis was performed to assess significant differences between treatment conditions and untreated control-fractions using the one sample t-test on GraphPad Prism software platform (GraphPad, La Jolla, CA, USA).
RESULTS
Antiproliferative and apoptosis-inducing activity of omacetaxine in TKI-sensitive and -resistant cell lines Trypan-blue dye exclusion counts and MTS-assays were performed to characterize the antiproliferative activity of OM in vitro. The murine lymphoid cell line Ba/F3p210 transfected with BCR-ABL, and its mutant derivative Ba/F3p210-T315I as well as the BCR-ABL-negative control cell line Ba/F3pSRa were used. Furthermore we tested the BCR-ABL-positive murine myeloid cell lines 32Dp210 and 32Dp210-T315I, and the human blast crisis cell line KBM5s and its imatinib-resistant derivative KBM5r-T315I.
For dye exclusion experiments cells were incubated up to 48 h with increasing concentrations of OM up to 1000 nM. BCR-ABLexpression sensitizes lymphoid Ba/F3-cells significantly to OM as shown by comparison of the respective IC 50 -values (10 nM (Ba/F3p210) vs 66.7 nM (Ba/F3pSRa); Po0.05). However, expression of BCR-ABL-mutant T315I confers cross-resistance to OM with a fivefold increased IC 50 -value (IC 50 : 56.5 nM). This genotype-induced difference was not observed in the myeloid cell lines 32Dp210 and 32Dp210-T315I showing similar IC 50 -values (Figure 1a) . Additionally dye exclusion counts were performed with the CML-blast crisis cell line K562. Data are summarized in Table 1 . Data generated by the MTS-proliferation assays largely confirmed the trypan-blue exclusion assay results (Table 1, Figure 1b) .
To investigate the cellular mechanisms leading to growth inhibition in the presence of omacetaxine, cells were incubated with OM for 48 h followed by flow cytometric detection of activated caspase-3. In line with results from proliferation assays, expression of BCR-ABL in the murine Ba/F3p210 cells sensitizes to OM with a significant increase of caspase-3-mediated apoptosis in Ba/F3p210 cells compared with vector control. Accordingly, OM-dependent apoptosis is significantly less pronounced in Ba/F3p210-T315I cells compared with Ba/F3p210 confirming cross-resistance of the T315I-mutant against OM. In the human myeloid cell line KBM5r-T315I, the presence of BCR-ABL-T315I does not negatively impact on apoptosis induction by OM (Table 1, Figure 1c ).
Omacetaxine overcomes cytokine-rescue of BCR-ABL þ cells and partially deprives cells from cytokine-rescue in the presence of nilotinib As BCR-ABL-expression negatively regulates cCRbc-expression, which is the central component of the IL3-receptor, and thereby forces BCR-ABL-transformed cells into a BCR-ABL-addicted state, 22 our aim was to investigate the cCRbc-expression in response to OM. Known negative impact of BCR-ABL on cCRbc-expression was confirmed in our cell line model (Figure 2 ). Whereas vector control cells that depend on IL3 for proliferation express high levels of cCRbc, basal expression of BCR-ABL-transduced Ba/F3p210 and even more so of Ba/F3p210-T315I-cells show markedly decreased cCRbc-expression. Treatment with 40 nM leads to upregulation in cytokine dependent vector only cells, but imparts cCRbc-suppression in BCR-ABL-transduced cells ( Figure 2 ).
Next, we analyzed cCRbc-expression in 32Dp210 and 32Dp210-T315I cells after exposure to OM for 48 h. Similarly to the results in the BCR-ABL-positive Ba/F3 cell lines, we found a marked suppression of cCRbc-protein expression to near extinction at clinically achievable concentrations of 40 nM (Figure 3a) . These data suggest, that OM promotes antileukemic action in BCR-ABLtransformed cells in part by interference with the BCR-ABLinteracting cytokine signaling axis that is headed by cCRbc.
To corroborate this finding in primary leukemic cells, patient derived CD34 þ enriched CML-progenitor cells (n ¼ 3) were treated with OM for 24 h in the presence of a physiological GF mix. In line with the cell line data, OM suppresses cCRbc-protein expression in CD34 þ CML-progenitor cells at 50 nM (Po0.05, Figure 3b) .
In order to functionally assess the effects of OM on cytokinemediated resistance in BCR-ABL-positive cell lines, we performed experiments in the absence and presence of IL3. As mentioned above IL3 is known to allow escape from TKI-treatment in our cell line models. 9, 23 Ba/F3p210 cells were exposed to OM alone or in combination with nilotinib in the presence or absence of IL3 for 48 h. Whereas addition of IL3 reverts cytotoxicity in Ba/F3p210 cells exposed to nilotinib as expected, IL3 is not able to inhibit the antiproliferative activity when OM is added (Figure 4a ). These experiments were also performed using the 32Dp210 cell line. Similarly, we found unaffected growth inhibition by OM when IL3 is present, but significant cytokine rescue from nilotinib. In combination experiments, OM at least partially overcame the survival stimulus in the IL3 containing cultures (Figure 4a ). In order to investigate the cytokine response in primary leukemia cells, CD34À enriched CML progenitors derived from patients with de novo, treatment naïve CML were treated in vitro. Here, OM shows effective inhibition of CD34 þ CML-progenitor viability at clinically relevant concentrations of 50 nM in the presence of a physiological GF mix (n ¼ 4, IC 50 : 39 nM). In line with the cell line experiments, GF-levels exceeding the low-physiological concentration range (high GF) do not affect OM-activity against leukemia cells, but the antiproliferative activity of nilotinib. In addition, OM is able to override resistance against nilotinib imparted by high GF concentrations (Figure 4b ).
TKI-induced upregulation of cCRbc is overcome by OM in Ba/F3p210 cells Pilot experiments collected evidence that TKIs induce upregulation of cCRbc-expression as possible mechanism to counteract antiproliferative activity of BCR-ABL-targeted therapy (see Supplementary Figure 1) . 11 To investigate the ability of OM to modulate this cellular response to TKI-treatment, we performed combination experiments with nilotinib and OM ( Figure 5 ). Here we observed near eradication of cCRbc in the presence of low-nanomolar concentrations OM, even in the presence of the TKI. Thus, OM deprives BCR-ABL-transformed cells from the potential to upregulate a compensatory cytokine pathway that might be able to be a feeding ground for resistance.
OM-dependent downregulation of cCRbc-expression is regulated by proteasomal degradation OM inhibits protein synthesis at the step of initiation and elongation of protein chains at the ribosome and triggers degradation of short-lived proteins through the proteasome. 24 To define the role of proteasomal degradation for the OM-induced cCRbc-downregulation in hematopoietic cells, we performed combination experiments with the proteasome-inhibitor MG-132 and OM. For this end we treated Ba/F3p210 cells with 10 mM MG-132 1 h prior adding 50 nM of OM. Total cell lysates were generated after 16 h of incubation. Western blot analysis of total cCRbc-levels showed that proteasome inhibition by MG-132 partially restores OM-mediated reduction of cCRbc-protein-levels, by blocking OM-induced proteasomal degradation (Figure 6a) .
To further investigate whether OM regulates cCRbc-expression on the mRNA level, quantitative PCR analysis was performed on CD34 þ CML-progenitors of chronic phase patients (n ¼ 3). As shown in Figure 6b , OM does not significantly affect mRNAexpression of cCRbc. Instead we found a trend towards upregulation of cCRbc-mRNA-levels in response to OM.
DISCUSSION
We sought to investigate the effects of OM on hematopoietic cell lines expressing nonmutated and mutated BCR-ABL as well as primary CD34 þ CML-progenitor cells. Our key finding is the proteasomal downregulation of the common cytokine receptor subunit bc in BCR-ABL-transformed hematopoietic cell lines including the pan-TKI-resistant T315I-mutant, as well as in primary human CML progenitor cells. This marked downregulation goes along with functional relevance, in that addition of IL3 in cell lines or addition of a physiological cytokine mix in primary progenitor cultures does not confer resistance to OM as it does in nilotinibtreated cultures. Furthermore, combination experiments using OM in conjunction with nilotinib demonstrate the capability of OM to eliminate cytokine-induced resistance (Figures 4a and b) . These observations have several implications.
Growth factor signaling as modulator of TKI response has been shown in several studies on ex vivo treated CML CD34 þ progenitor cells. 7,25 --28 Hence, the microenvironment as major source of growth factors is probably a crucial factor underlying resistance development. Primitive CML progenitor cells from some patients with complete cytogenetic response have been shown to carry resistance mutations, suggesting that resistance originates in this cell fraction, which is in intimate contact with the stem cell niche. 29, 30 Currently, novel agents or novel drug combinations are being evaluated for their potential to overcome stem cell resistance in TKI-treated CML. 31 However, cytokine-directed strategies have not evolved. Our experiments using the plantderived agent OM indicate the potential of OM to target cytokinedependent resistance. That is, interference with cytokine signaling at the initiation point of the cytokine cascade, the receptor itself. Consistent with previous reports, OM depletes the cells of the protein of interest not only by prevention of synthesis, but also by induction of proteasomal degradation, as we show by demonstration of re-expression of cCRbc in the presence of the proteasome inhibitor MG-132 (Figure 6a) . 32 Several points of convergence between cCRbc-and BCR-ABL-dependent signaling have been reported, which explains their overlapping pro-survival and proliferative activity in hematopoietic cells. 2 Transformation of factor-dependent cells by BCR-ABL leads to downregulation of cCRbc. 22 This impairment of cytokine supported survival addicts cells to the oncogenic action of BCR-ABL, which in part explains the pro-apoptotic activity of BCR-ABL-directed inhibitors. Vice versa, upregulation of cCRbc in response to BCR-ABL-inhibition is plausible as potential mechanism of resistance, and correlates with the ability of cytokines to rescue leukemic cells from apoptosis. 11 Our data on primary CD34 þ ---enriched progenitors cells support a role of cCRbc-regulation in the development of resistance in vivo, but this still needs to be confirmed.
Preferential downregulation of cCRbc in cells expressing the gatekeeper mutant T315I (compared with cells expressing nonmutated BCR-ABL; Figure 2 ) might be of importance with regard to reported paracrine resistance regulation in BCR-ABL-mutant cells. 33 Our data therefore offer an in vitro explanation for the observed deselection of T315I-mutant cells in patients treated with OM, where such a paracrine mechanism might have been operational. 12 However, whether this can be confirmed in vivo needs to be shown.
At least ex vivo, primary CD34-enriched progenitor cells respond to OM-treatment similarly compared with the cell line experiments with significant downregulation of cCRbc (Figure 3b) , and functionally, with negative regulation of cytokine rescue (Figure 4b ). These results are in line with recent data on the stem cell activity of OM. 34 Whereas Allan et al. explain the observed stem cell activity of OM in part by negative regulation of antiapoptotic molecules such as Mcl-2, OM might also prevent stem cell survival through interruption of cytokine-stimulated survival signals by depriving the leukemic cells from the cytokine receptor. As it has been shown that survival of CML stem cells does not depend on BCR-ABL-activity but on cytokines, targeting of cCRbc might be a means to overcome this Achilles heel of BCR-ABLdirected TKIs. 35 In summary, our data provide preclinical evidence that OM targets cCRbc and prevents cytokine-dependent protection of CML-cells treated with TKIs. Whether cCRbc is a relevant target to optimize stem cell activity of TKI-treatment, and whether OM is an useful agent to improve TKI-based treatment merits further evaluation. 
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